Skip to main content

Articles

Page 6 of 25

  1. The antihypertensive angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) have similar indications and mechanisms of action, but prior work suggests divergence in their ef...

    Authors: Michael Ouk, Che-Yuan Wu, Jennifer S. Rabin, Aaron Jackson, Jodi D. Edwards, Joel Ramirez, Mario Masellis, Richard H. Swartz, Nathan Herrmann, Krista L. Lanctôt, Sandra E. Black and Walter Swardfager
    Citation: Alzheimer's Research & Therapy 2021 13:43
  2. PET imaging of glucose metabolism has revealed presymptomatic abnormalities in genetic FTD but has not been explored in MAPT P301L mutation carriers. This study aimed to explore the patterns of presymptomatic hyp...

    Authors: Mica T. M. Clarke, Frédéric St-Onge, Jean-Mathieu Beauregard, Martina Bocchetta, Emily Todd, David M. Cash, Jonathan D. Rohrer and Robert Laforce Jr
    Citation: Alzheimer's Research & Therapy 2021 13:42
  3. Observational studies suggest that the use of antihypertensive medications (AHMs) is associated with a reduced risk of Alzheimer’s disease (AD); however, these findings may be biased by confounding and reverse...

    Authors: Ya-Nan Ou, Yu-Xiang Yang, Xue-Ning Shen, Ya-Hui Ma, Shi-Dong Chen, Qiang Dong, Lan Tan and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2021 13:41
  4. The neuropathological hallmarks of Alzheimer’s disease (AD) are amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs). The amyloid cascade theory is the leading hypothesis of AD pathology. Aβ deposition pr...

    Authors: Yanxing Chen, Shuai Zhao, Ziqi Fan, Zheyu Li, Yueli Zhu, Ting Shen, Kaicheng Li, Yaping Yan, Jun Tian, Zhirong Liu and Baorong Zhang
    Citation: Alzheimer's Research & Therapy 2021 13:40
  5. Current tasks measuring social cognition are usually ‘pen and paper’ tasks, have ceiling effects and include complicated test instructions that may be difficult to understand for those with cognitive impairmen...

    Authors: Lucy L. Russell, Caroline V. Greaves, Rhian S. Convery, Jennifer Nicholas, Jason D. Warren, Diego Kaski and Jonathan D. Rohrer
    Citation: Alzheimer's Research & Therapy 2021 13:39
  6. Elevated cerebrospinal fluid (CSF) concentrations of total tau (T-tau) and phosphorylated tau at Thr181 (P-tau181) protein are typical of Alzheimer’s disease (AD). However, the T-tau assay measures only the mi...

    Authors: Claudia Cicognola, Oskar Hansson, Philip Scheltens, Hlin Kvartsberg, Henrik Zetterberg, Charlotte E. Teunissen and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2021 13:38
  7. Synaptic failure is one of the principal events associated with cognitive dysfunction in Alzheimer’s disease (AD). Preservation of existing synapses and prevention of synaptic loss are promising strategies to ...

    Authors: Panchanan Maiti, Zackary Bowers, Ali Bourcier-Schultz, Jarod Morse and Gary L. Dunbar
    Citation: Alzheimer's Research & Therapy 2021 13:37

    The Correction to this article has been published in Alzheimer's Research & Therapy 2022 14:42

  8. β-amyloid (Aβ) and tau positron emission tomography (PET) detect the pathological changes that define Alzheimer’s disease (AD) in living people. Cognitive measures sensitive to Aβ and tau burden may help strea...

    Authors: Elena Tsoy, Amelia Strom, Leonardo Iaccarino, Sabrina J. Erlhoff, Collette A. Goode, Anne-Marie Rodriguez, Gil D. Rabinovici, Bruce L. Miller, Joel H. Kramer, Katherine P. Rankin, Renaud La Joie and Katherine L. Possin
    Citation: Alzheimer's Research & Therapy 2021 13:36
  9. The mechanism of synaptic loss in Alzheimer’s disease is poorly understood and may be associated with tau pathology. In this combined positron emission tomography (PET) and magnetoencephalography (MEG) study, ...

    Authors: Emma M. Coomans, Deborah N. Schoonhoven, Hayel Tuncel, Sander C. J. Verfaillie, Emma E. Wolters, Ronald Boellaard, Rik Ossenkoppele, Anouk den Braber, Wiep Scheper, Patrick Schober, Steven P. Sweeney, J. Michael Ryan, Robert C. Schuit, Albert D. Windhorst, Frederik Barkhof, Philip Scheltens…
    Citation: Alzheimer's Research & Therapy 2021 13:35
  10. Identification of genetic risk factors that are shared between Alzheimer’s disease (AD) and other traits, i.e., pleiotropy, can help improve our understanding of the etiology of AD and potentially detect new t...

    Authors: William P. Bone, Katherine M. Siewert, Anupama Jha, Derek Klarin, Scott M. Damrauer, Kyong-Mi Chang, Philip S. Tsao, Themistocles L. Assimes, Marylyn D. Ritchie and Benjamin F. Voight
    Citation: Alzheimer's Research & Therapy 2021 13:34
  11. Physical inactivity has been consistently linked to increased risk of cognitive decline; however, studies examining the impact of exercise interventions on cognition have produced inconsistent findings. Some o...

    Authors: Belinda M. Brown, Natalie Frost, Stephanie R. Rainey-Smith, James Doecke, Shaun Markovic, Nicole Gordon, Michael Weinborn, Hamid R. Sohrabi, Simon M. Laws, Ralph N. Martins, Kirk I. Erickson and Jeremiah J. Peiffer
    Citation: Alzheimer's Research & Therapy 2021 13:33
  12. Prominent activation of microglial immune/inflammatory processes is a characteristic feature of brains of patients with tauopathies including Alzheimer’s disease (AD), suggesting that neuroinflammation may be ...

    Authors: Yun-Beom Choi, Ambrose A. Dunn-Meynell, Michelle Marchese, Benjamin M. Blumberg, Deeya Gaindh, Peter C. Dowling and Wei Lu
    Citation: Alzheimer's Research & Therapy 2021 13:32
  13. APOE ε4 carrier status is known to increase odds of amnestic presentations with Alzheimer’s pathology. It is unknown how APOE ε4 carrier status impacts odds of specific initial cognitive symptoms in the presence ...

    Authors: Jagan A. Pillai, James Bena, Aaron Bonner-Jackson and James B. Leverenz
    Citation: Alzheimer's Research & Therapy 2021 13:31
  14. Circulating autoantibodies and sex-dependent discrepancy in prevalence are unexplained phenomena of Alzheimer’s disease (AD). Using the 3xTg-AD mouse model, we reported that adult males show early manifestatio...

    Authors: Minesh Kapadia, M. Firoz Mian, Donglai Ma, Craig P. Hutton, Amber Azam, Klotilda Narkaj, Chuanhai Cao, Breanna Brown, Bernadeta Michalski, David Morgan, Paul Forsythe, Iva B. Zovkic, Margaret Fahnestock and Boris Sakic
    Citation: Alzheimer's Research & Therapy 2021 13:30
  15. White matter hyperintensities (WMH) are frequently found in Alzheimer’s disease (AD). Commonly considered as a marker of cerebrovascular disease, regional WMH may be related to pathological hallmarks of AD, in...

    Authors: Malo Gaubert, Catharina Lange, Antoine Garnier-Crussard, Theresa Köbe, Salma Bougacha, Julie Gonneaud, Robin de Flores, Clémence Tomadesso, Florence Mézenge, Brigitte Landeau, Vincent de la Sayette, Gaël Chételat and Miranka Wirth
    Citation: Alzheimer's Research & Therapy 2021 13:29
  16. The brain’s dynamic spontaneous neural activity and dynamic functional connectivity (dFC) are both important in supporting cognition, but how these two types of brain dynamics evolve and co-evolve in subjectiv...

    Authors: Lingyan Liang, Yueming Yuan, Yichen Wei, Bihan Yu, Wei Mai, Gaoxiong Duan, Xiucheng Nong, Chong Li, Jiahui Su, Lihua Zhao, Zhiguo Zhang and Demao Deng
    Citation: Alzheimer's Research & Therapy 2021 13:28
  17. Neuroimaging studies of autosomal dominant Alzheimer’s disease (ADAD) enable characterization of the trajectories of cerebral amyloid-β (Aβ) and tau accumulation in the decades prior to clinical symptom onset....

    Authors: Justin S. Sanchez, Bernard J. Hanseeuw, Francisco Lopera, Reisa A. Sperling, Ana Baena, Yamile Bocanegra, David Aguillon, Edmarie Guzmán-Vélez, Enmanuelle Pardilla-Delgado, Liliana Ramirez-Gomez, Clara Vila-Castelar, Jairo E. Martinez, Joshua T. Fox-Fuller, Claudia Ramos, Martin Ochoa-Escudero, Sergio Alvarez…
    Citation: Alzheimer's Research & Therapy 2021 13:27
  18. Whether in the context of monitoring disease progression or in assessing the effects of interventions, a major challenge in dementia research is determining when an individual has undergone meaningful change i...

    Authors: Aja Louise Murray, Marlena Vollmer, Ian J. Deary, Graciela Muniz-Terrera and Tom Booth
    Citation: Alzheimer's Research & Therapy 2021 13:26
  19. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Julia Stockmann, Inge M. W. Verberk, Nina Timmesfeld, Robin Denz, Brian Budde, Julia Lange-Leifhelm, Philip Scheltens, Wiesje M. van der Flier, Andreas Nabers, Charlotte E. Teunissen and Klaus Gerwert
    Citation: Alzheimer's Research & Therapy 2021 13:25

    The original article was published in Alzheimer's Research & Therapy 2020 12:169

  20. Recent DNA/RNA sequencing and other multi-omics technologies have advanced the understanding of the biology and pathophysiology of AD, yet there is still a lack of disease-modifying treatments for AD. A new ap...

    Authors: Yadi Zhou, Jiansong Fang, Lynn M. Bekris, Young Heon Kim, Andrew A. Pieper, James B. Leverenz, Jeffrey Cummings and Feixiong Cheng
    Citation: Alzheimer's Research & Therapy 2021 13:24
  21. The differential diagnosis of frontotemporal dementia (FTD) and Alzheimer’s disease (AD) is difficult due to the overlaps of clinical symptoms. Structural magnetic resonance imaging (sMRI) presents distinct br...

    Authors: Qun Yu, Yingren Mai, Yuting Ruan, Yishan Luo, Lei Zhao, Wenli Fang, Zhiyu Cao, Yi Li, Wang Liao, Songhua Xiao, Vincent C. T. Mok, Lin Shi and Jun Liu
    Citation: Alzheimer's Research & Therapy 2021 13:23
  22. Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarker cutoffs from immunoassays with low interlaboratory variability in diverse ethnic groups are necessary for their use in clinics and clinical trials. ...

    Authors: Sohee Moon, Sujin Kim, Sakulrat Mankhong, Seong Hye Choi, Manu Vandijck, Vesna Kostanjevecki, Jee Hyang Jeong, Soo Jin Yoon, Kyung Won Park, Eun-Joo Kim, Bora Yoon, Hee Jin Kim, Jae-Won Jang, Jin Yong Hong, Dong-Ho Park, Leslie M. Shaw…
    Citation: Alzheimer's Research & Therapy 2021 13:22
  23. Association between kidney dysfunction and dementia has been studied in western cohorts, but with inconsistent conclusions which may be due to the different measurements of kidney function. We aim to verify th...

    Authors: Mengjing Wang, Ding Ding, Qianhua Zhao, Wanqing Wu, Zhenxu Xiao, Xiaoniu Liang, Jianfeng Luo and Jing Chen
    Citation: Alzheimer's Research & Therapy 2021 13:21
  24. Both serotonergic signalling disruption and systemic inflammation have been associated with the pathogenesis of Alzheimer’s disease (AD). The common denominator linking the two is the catabolism of the essenti...

    Authors: Luke Whiley, Katie E. Chappell, Ellie D’Hondt, Matthew R. Lewis, Beatriz Jiménez, Stuart G. Snowden, Hilkka Soininen, Iwona Kłoszewska, Patrizia Mecocci, Magda Tsolaki, Bruno Vellas, Jonathan R. Swann, Abdul Hye, Simon Lovestone, Cristina Legido-Quigley and Elaine Holmes
    Citation: Alzheimer's Research & Therapy 2021 13:20
  25. Due to heterogeneous clinical presentation, difficult differential diagnosis with Alzheimer’s disease (AD) and psychiatric disorders, and evolving clinical criteria, the epidemiology and natural history of fro...

    Authors: Mélanie Leroy, Maxime Bertoux, Emilie Skrobala, Elisa Mode, Catherine Adnet-Bonte, Isabelle Le Ber, Stéphanie Bombois, Pascaline Cassagnaud, Yaohua Chen, Vincent Deramecourt, Florence Lebert, Marie Anne Mackowiak, Adeline Rollin Sillaire, Marielle Wathelet, Florence Pasquier and Thibaud Lebouvier
    Citation: Alzheimer's Research & Therapy 2021 13:19
  26. Blood-based biomarkers for Alzheimer’s disease (AD) are highly needed in clinic practice. So far, the gold standards for AD diagnosis are brain neuroimaging and beta-amyloid peptide, total tau, and phosphoryla...

    Authors: Maria Patrícia A. Oliveira Monteiro, Danielle S. M. Salheb Oliveira, Patrícia R. Manzine, Carla M. Crispim Nascimento, Ariene A. dos Santos Orlandi, Grace A. de Oliveira Gomes, Fabiana dos Santos Orlandi, Marisa S. Zazzetta, Henrique Pott-Junior and Marcia R. Cominetti
    Citation: Alzheimer's Research & Therapy 2021 13:18
  27. Recent studies suggest that plasma phosphorylated tau181 (p-tau181) is a highly specific biomarker for Alzheimer’s disease (AD)-related tau pathology. It has great potential for the diagnostic and prognostic e...

    Authors: Anna Zettergren, Jodie Lord, Nicholas J. Ashton, Andrea L. Benedet, Thomas K. Karikari, Juan Lantero Rodriguez, Anniina Snellman, Marc Suárez-Calvet, Petroula Proitsi, Henrik Zetterberg and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2021 13:17
  28. Early study exit is detrimental to statistical power and increases the risk for bias in Alzheimer’s disease clinical trials. Previous analyses in early phase academic trials demonstrated associations between r...

    Authors: Olivia M. Bernstein, Joshua D. Grill and Daniel L. Gillen
    Citation: Alzheimer's Research & Therapy 2021 13:16
  29. Genome-wide association studies have identified more than 30 Alzheimer’s disease (AD) risk genes, although the detailed mechanism through which all these genes are associated with AD pathogenesis remains unkno...

    Authors: Meng-Shan Tan, Yu-Xiang Yang, Wei Xu, Hui-Fu Wang, Lin Tan, Chuan-Tao Zuo, Qiang Dong, Lan Tan, John Suckling and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2021 13:15
  30. We aimed to derive an algorithm to define the optimal proportion of patients with mild cognitive impairment (MCI) in whom cerebrospinal fluid (CSF) testing is of added prognostic value.

    Authors: Ingrid S. van Maurik, Hanneke F. M. Rhodius-Meester, Charlotte E. Teunissen, Philip Scheltens, Frederik Barkhof, Sebastian Palmqvist, Oskar Hansson, Wiesje M. van der Flier and Johannes Berkhof
    Citation: Alzheimer's Research & Therapy 2021 13:14
  31. Alzheimer’s disease (AD) and behavioral variant frontotemporal dementia (bvFTD) cause distinct atrophy and functional disruptions within two major intrinsic brain networks, namely the default network and the s...

    Authors: Adeline Su Lyn Ng, Juan Wang, Kwun Kei Ng, Joanna Su Xian Chong, Xing Qian, Joseph Kai Wei Lim, Yi Jayne Tan, Alisa Cui Wen Yong, Russell Jude Chander, Shahul Hameed, Simon Kang Seng Ting, Nagaendran Kandiah and Juan Helen Zhou
    Citation: Alzheimer's Research & Therapy 2021 13:13
  32. Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by the hallmark finding of cerebral amyloid deposition. Many researchers have tried to predict the existence of cerebral amyl...

    Authors: Jong-Chan Park, Keum Sim Jung, Jiyeong Kim, Ji Sung Jang, Sunghoon Kwon, Min Soo Byun, Dahyun Yi, Gihwan Byeon, Gijung Jung, Yu Kyeong Kim, Dong Young Lee, Sun-Ho Han and Inhee Mook-Jung
    Citation: Alzheimer's Research & Therapy 2021 13:12
  33. Attempts to associate amyloid-β (Aβ) pathogenesis with synaptic loss in Alzheimer’s disease (AD) have thus far been limited to small numbers of postmortem studies. Aβ plaque burden is not well-correlated with ...

    Authors: Ryan S. O’Dell, Adam P. Mecca, Ming-Kai Chen, Mika Naganawa, Takuya Toyonaga, Yihuan Lu, Tyler A. Godek, Joanna E. Harris, Hugh H. Bartlett, Emmie R. Banks, Victoria L. Kominek, Wenzhen Zhao, Nabeel B. Nabulsi, Jim Ropchan, Yunpeng Ye, Brent C. Vander Wyk…
    Citation: Alzheimer's Research & Therapy 2021 13:11
  34. Cholinesterase inhibitors (ChEIs) are an FDA-approved symptomatic treatment for patients with Alzheimer’s disease (AD). Its efficacy in patients with mild cognitive impairment (MCI), however, is controversial....

    Authors: Jung-Min Pyun, Nayoung Ryoo, Young Ho Park and SangYun Kim
    Citation: Alzheimer's Research & Therapy 2021 13:10
  35. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia in the world. Microglia are the innate immune cells of CNS; their proliferation, activation, and surviv...

    Authors: Vincent Pons, Pascal Lévesque, Marie-Michèle Plante and Serge Rivest
    Citation: Alzheimer's Research & Therapy 2021 13:8
  36. Alzheimer’s disease (AD) is an intractable neurodegenerative disorder in the elderly population, currently lacking a cure. Trichostatin A (TSA), a histone deacetylase inhibitor, showed some neuroprotective rol...

    Authors: Qiang Su, Tian Li, Pei-Feng He, Xue-Chun Lu, Qi Yu, Qi-Chao Gao, Zhao-Jun Wang, Mei-Na Wu, Dan Yang and Jin-Shun Qi
    Citation: Alzheimer's Research & Therapy 2021 13:7
  37. Molecular tweezers (MTs) are broad-spectrum inhibitors of abnormal protein aggregation. A lead MT, called CLR01, has been demonstrated to inhibit the aggregation and toxicity of multiple amyloidogenic proteins...

    Authors: Jing Di, Ibrar Siddique, Zizheng Li, Ghattas Malki, Simon Hornung, Suman Dutta, Ian Hurst, Ella Ishaaya, Austin Wang, Sally Tu, Ani Boghos, Ida Ericsson, Frank-Gerrit Klärner, Thomas Schrader and Gal Bitan
    Citation: Alzheimer's Research & Therapy 2021 13:6

    The Correction to this article has been published in Alzheimer's Research & Therapy 2021 13:88

  38. Approximately 25% of the general population carries at least one ε4 allele of the Apolipoprotein E (APOE ε4), the strongest genetic risk factor for late onset Alzheimer’s disease. Beyond its association with late...

    Authors: Amin Gharbi-Meliani, Aline Dugravot, Séverine Sabia, Melina Regy, Aurore Fayosse, Alexis Schnitzler, Mika Kivimäki, Archana Singh-Manoux and Julien Dumurgier
    Citation: Alzheimer's Research & Therapy 2021 13:5
  39. Hyposmia in Alzheimer’s disease (AD) is a typical early symptom according to numerous previous clinical studies. Although amyloid-β (Aβ), which is one of the toxic factors upregulated early in AD, has been ide...

    Authors: Gowoon Son, Seung-Jun Yoo, Shinwoo Kang, Ameer Rasheed, Da Hae Jung, Hyunjun Park, Bongki Cho, Harry W. M. Steinbusch, Keun-A Chang, Yoo-Hun Suh and Cheil Moon
    Citation: Alzheimer's Research & Therapy 2021 13:4
  40. The memory impairments in mild cognitive impairment (MCI) can be classified into encoding (EF) and retrieval (RF) failure, which can be affected by underlying pathomechanism. We explored the differences struct...

    Authors: Su-Hyun Han, Jung-Min Pyun, Soeun Yeo, Dong Won Kang, Ho Tae Jeong, Seung Wan Kang, SangYun Kim and Young Chul Youn
    Citation: Alzheimer's Research & Therapy 2021 13:3
  41. As Alzheimer’s disease (AD) pathology presents decades before dementia manifests, unbiased biomarker cut-points may more closely reflect presence of pathology than clinically defined cut-points. Currently, unb...

    Authors: Flora H. Duits, Kirsten E. J. Wesenhagen, Laura Ekblad, Emma Wolters, Eline A. J. Willemse, Philip Scheltens, Wiesje M. van der Flier, Charlotte E. Teunissen, Pieter Jelle Visser and Betty M. Tijms
    Citation: Alzheimer's Research & Therapy 2021 13:2
  42. COVID-19 is primarily a respiratory disease but up to two thirds of hospitalised patients show evidence of central nervous system (CNS) damage, predominantly ischaemic, in some cases haemorrhagic and occasiona...

    Authors: Scott Miners, Patrick G. Kehoe and Seth Love
    Citation: Alzheimer's Research & Therapy 2020 12:170
  43. We evaluated Aβ misfolding in combination with Aβ42/40 ratio as a prognostic tool for future clinical progression to mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD) in individuals with...

    Authors: Julia Stockmann, Inge M. W. Verberk, Nina Timmesfeld, Robin Denz, Brian Budde, Julia Lange-Leifhelm, Philip Scheltens, Wiesje M. van der Flier, Andreas Nabers, Charlotte E. Teunissen and Klaus Gerwert
    Citation: Alzheimer's Research & Therapy 2020 12:169

    The Correction to this article has been published in Alzheimer's Research & Therapy 2021 13:25

  44. Neurogranin (Ng) is a neuron-specific and postsynaptic protein that is abundantly expressed in the brain, particularly in the dendritic spine of the hippocampus and cerebral cortex. The enzymatic cleavage of N...

    Authors: Annika Öhrfelt, Julien Dumurgier, Henrik Zetterberg, Agathe Vrillon, Nicholas J. Ashton, Hlin Kvartsberg, Elodie Bouaziz-Amar, Jacques Hugon, Claire Paquet and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2020 12:168
  45. Subjective cognitive decline (SCD) is recognized as a risk stage for Alzheimer’s disease (AD) and other dementias, but its prevalence is not well known. We aimed to use uniform criteria to better estimate SCD ...

    Authors: Susanne Röhr, Alexander Pabst, Steffi G. Riedel-Heller, Frank Jessen, Yuda Turana, Yvonne S. Handajani, Carol Brayne, Fiona E. Matthews, Blossom C. M. Stephan, Richard B. Lipton, Mindy J. Katz, Cuiling Wang, Maëlenn Guerchet, Pierre-Marie Preux, Pascal Mbelesso, Karen Ritchie…
    Citation: Alzheimer's Research & Therapy 2020 12:167
  46. Alzheimer’s disease (AD) has been a devastating public health with the development of global aging. Approaches for reducing the current AD epidemic are becoming a primary focus of human healthcare due to the l...

    Authors: Mengtian Guo, Zhenyu Yin, Fanglian Chen and Ping Lei
    Citation: Alzheimer's Research & Therapy 2020 12:109
  47. The LipiDiDiet trial showed that Souvenaid, a medical food, might delay progression to dementia in prodromal Alzheimer’s disease (AD). The objective of this study was to assess the cost-utility of Souvenaid co...

    Authors: Javier Mar, Ania Gorostiza, Oliver Ibarrondo, Igor Larrañaga, Arantzazu Arrospide, Pablo Martinez-Lage and Myriam Soto-Gordoa
    Citation: Alzheimer's Research & Therapy 2020 12:166